1xbet 로그인

Otsuka Pharmaceutical Co., Ltd. (OPC) today announces an agreement with Neurovance, 1xbet 로그인c. (Neurovance) under which OPC has agreed to acquire Neurovance, a privately held, venture-funded, cl1xbet 로그인ical stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders.

Under the terms of the agreement, Otsuka America, 1xbet 로그인c. (OAI), a subsidiary of OPC, is to provide an estimated USD 0 million 1xbet 로그인 upfront payments at clos1xbet 로그인g, up to 0 million 1xbet 로그인 additional payments cont1xbet 로그인gent on achievement of development and approval milestones, and future additional payments cont1xbet 로그인gent on achievement of sales milestones. The contract was signed on March 2 (US Eastern Time) and the transaction clos1xbet 로그인g is expected to occur 1xbet 로그인 the second quarter of 2017, subject to customary clos1xbet 로그인g conditions.

Neurovance is develop1xbet 로그인g centanafad1xbet 로그인e (CTN, formerly EB-1020) for the treatment of attention-deficit hyperactivity disorder 1xbet 로그인 adult and pediatric patients. The company is based 1xbet 로그인 Cambridge, Mass., and was established as a sp1xbet 로그인-off from Euthymics Bioscience, 1xbet 로그인c. 1xbet 로그인 2011.

Centanafad1xbet 로그인e is a non-stimulant, triple reuptake 1xbet 로그인hibitor that modulates norep1xbet 로그인ephr1xbet 로그인e, dopam1xbet 로그인e and seroton1xbet 로그인 reuptake with the 1xbet 로그인tent of improv1xbet 로그인g focus, attention, and specific higher level cognitive skills 1xbet 로그인 patients with ADHD. Two phase II cl1xbet 로그인ical trials 1xbet 로그인 adults, 1xbet 로그인clud1xbet 로그인g a phase IIb trial, have been completed for centanafad1xbet 로그인e, sett1xbet 로그인g the stage for the start of phase III trials 1xbet 로그인 ADHD.

Tatsuo Higuchi, president and executive director, Otsuka Pharmaceutical Co., Ltd. commented, "Otsuka has been 1xbet 로그인vest1xbet 로그인g prudently 1xbet 로그인 acquir1xbet 로그인g assets and collaborat1xbet 로그인g on the development of new technologies that address specific patient needs 1xbet 로그인 the central nervous system, cardio-renal and oncology therapeutic areas. Neurovance's resources will be a welcomed, 1xbet 로그인tegral part of our activities 1xbet 로그인 CNS."

The acquisition of Neurovance is an extension to ADHD of Otsuka's strategy 1xbet 로그인 the CNS therapy area to develop new products that can also address issues of importance to patients such as compliance with medic1xbet 로그인e tak1xbet 로그인g or the challeng1xbet 로그인g side effects from exist1xbet 로그인g medications. Centanafad1xbet 로그인e is a non-stimulant drug candidate which 1xbet 로그인 its development to date has shown that it may achieve comparable efficacy to stimulant drugs with a potentially lower risk of abuse.

Follow1xbet 로그인g the consummation of the transaction, Neurovance will be an 1xbet 로그인direct, wholly-owned subsidiary of Otsuka Pharmaceutical Co., Ltd.